±¹³»µµ¼
Àü°øµµ¼/´ëÇб³Àç
ÀǾàÇа£È£°è¿
Á¤°¡ |
150,000¿ø |
---|
135,000¿ø (10%ÇÒÀÎ)
1,500P (1%Àû¸³)
ÇÒÀÎÇýÅÃ | |
---|---|
Àû¸³ÇýÅà |
|
|
|
Ãß°¡ÇýÅÃ |
|
À̺¥Æ®/±âȹÀü
¿¬°üµµ¼
»óǰ±Ç
ÀÌ»óǰÀÇ ºÐ·ù
Ã¥¼Ò°³
¡º¾àó¹æÀÇ Á¤¼®: Drug Class Review & Real World ¼¼Æ®¡»´Â ´Ü¼øÈ÷ ¾à¿¡ ´ëÇÑ Á¤º¸¸¸À» Á¦°øÇϱâ À§ÇÑ Ã¥Àº ¾Æ´Õ´Ï´Ù. ¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ¿¡¼ ÇÑ¹ß ´õ ³ª¾Æ°¡ °¡À̵å¶óÀÎÀ̳ª ±Ù°Å ±â¹ÝÀ¸·Î ¾àÀ» ó¹æÇÏ´Â ½ÇÀüÁöħÀ» Á¦½ÃÇÏ´Â °ÍÀÌ ÀÌ Ã¥ÀÇ ±Ã±ØÀûÀÎ ÁöÇâÁ¡ÀÔ´Ï´Ù. À̰ÍÀÌ ¹Ù·Î "Real world prescription"À̶ó´Â ºÎÁ¦¿¡ ´ã±ä ÀǹÌÀÔ´Ï´Ù.
¸ñÂ÷
Vol. 1
PART 1. ¿©·¯ °èÅë¿¡ µÎ·ç »ç¿ëµÇ´Â ¾à¹°
Chapter 01. ÀÚÀ²½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°
Topic 1. ÀÚÀ²½Å°æ°è -------- -------- 4
Topic 2. Äݸ° ¾à¹° -------- -------- 11
2-1. Äݸ° ÀÛ¿ëÁ¦ -------- 11
2-2. Äݸ° ±æÇ×Á¦ -------- 16
Topic 3. ¾Æµå·¹³¯¸° ¾à¹° -------- 21
3-1. ¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦ -------- 21
3-2. ¾Æµå·¹³¯¸° ±æÇ×Á¦ -------- 30
Chapter 02. Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å·ù
[SPECIAL REVIEW] Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å: °³¿ä -------- 38
Topic 4. NSAIDs -------- 42
Topic 5. Leukotriene Á¶ÀýÁ¦ -------- 49
Topic 6. ½ºÅ×·ÎÀ̵å -------- 53
Chapter 03. È÷½ºÅ¸¹Î/¼¼·ÎÅä´Ñ/Prostagladin
Topic 7. È÷½ºÅ¸¹Î/Ç×È÷½ºÅ¸¹ÎÁ¦ -------- 60
Topic 8. ¼¼·ÎÅä´Ñ -------- 71
Topic 9. Prostagladin -------- 77
Chapter 04. ÁøÅëÁ¦/ÅëÁõÄ¡·á
Topic 10. Non-opioid -------- 85
Topic 11. Opioid -------- 88
Topic 12. ¾Ï¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 97
Topic 13. ½Å°æº´¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 109
Chapter 05. Ç×»ýÁ¦/Ç×¾ÏÁ¦/¸é¿ª¾ïÁ¦Á¦
Topic 14. Ç×»ýÁ¦ -------- 124
Topic 15. Ç×¾ÏÁ¦ -------- 140
15-1. ¼¼Æ÷µ¶¼ºÇ×¾ÏÁ¦/¹é±Ý -------- 142
15-2. Ç×´ë»çÁ¦ -------- 144
15-3. Ç×¾Ï Ç×»ý¾à -------- 154
15-4. Plant alkaloid -------- 156
15-5. Ç¥ÀûÇ×¾ÏÁ¦ -------- 161
15-6. ¸é¿ªÇ×¾ÏÁ¦ -------- 164
Topic 16. ¸é¿ª¾ïÁ¦Á¦/¸é¿ªÁ¶ÀýÁ¦ -------- 167
PART 2. ½ÉÇ÷°ü/½ÅÀå
Chapter 01. [Drug Class Review] ½ÉÇ÷°ü/½ÅÀå¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÀÌ´¢Á¦(Diuretics) -------- 176
Topic 2. º£Å¸Â÷´ÜÁ¦(Beta blocker) -------- 195
Topic 3. Ä®½·Â÷´ÜÁ¦(Calcium channel blockers, calcium antagonists) -------- 208
Topic 4. ACEI & ARB -------- 221
Topic 5. Ç×Ç÷ÀüÁ¦(Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦, Ç÷Àü¿ëÇØÁ¦) -------- 236
5-1. Ç×Ç÷¼ÒÆÇÁ¦(Antiplatelet agents) -------- 236
5-2. Ç×ÀÀ°íÁ¦(Anticoagulants) -------- 249
5-3. Ç÷Àü¿ëÇØÁ¦(Thrombolytics) -------- 262
Topic 6. Ç÷°üÈ®ÀåÁ¦ -------- 264
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 10. °íÇ÷¾Ð(Hypertension) -------- 274
Topic 11. ºÎÁ¤¸Æ -------- 287
11-1. Ç׺ÎÁ¤¸ÆÁ¦ -------- 287
11-2. ºÎÁ¤¸ÆÀÇ ¾à¹°¿ä¹ý: Overview -------- 301
Topic 12. ½ÉºÎÀü -------- 302
[SPECIAL REVIEW] ARNI (Angiotensin Receptor Neprilysin Inhibitor) -------- 340
Topic 13. ÇãÇ÷¼º ½ÉÁúȯ -------- 348
[SUPPLEMENT] ÇãÇ÷¼º ½ÉÁúȯ ¿ä¾à -------- 351
PART 3. Ç÷¾×
Chapter 01. [Drug Class Review] Ç÷¾×°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. Ç÷¾×Á¦Á¦ -------- 384
Topic 2. ÁöÇ÷Á¦Á¦ -------- 389
Topic 3. Á¶Ç÷¼ºÀåÀÎÀÚ -------- 397
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ö°áÇ̺óÇ÷ -------- 406
Topic 5. °Å´ëÀûÇ÷¸ð±¸ºóÇ÷ -------- 418
Topic 6. ¸é¿ªÇ÷¼ÒÆÇ°¨¼ÒÁõ -------- 424
PART 4. È£Èí±â/¾Ë·¹¸£±â
Chapter 01. [Drug Class Review] È£Èí±â/¾Ë·¹¸£±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÁøÇذŴãÁ¦ -------- 436
1-1. ÁøÇØÁ¦ -------- 436
1-2. °Å´ãÁ¦ -------- 442
Topic 2. ±â°üÁöÈ®ÀåÁ¦ -------- 453
Topic 3. ±¹¼Ò ½ºÅ×·ÎÀ̵å: ÈíÀÔ ½ºÅ×·ÎÀ̵å -------- 462
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ¸¸¼º ±âħ -------- 468
[SUPPLEMENT] ¸¸¼º ±âħ: ÁÖ¿ä ¿øÀÎ Áúȯº° Ä¡·á -------- 475
Topic 5. ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD) -------- 484
[SUPPLEMENT] GOLD °¡À̵å¶óÀÎÀÇ º¯È -------- 496
[SUPPLEMENT] ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD): ±Þ¼º¾ÇÈ -------- 503
[SUPPLEMENT] Phosphodiesterase4 (PDE4) ¾ïÁ¦Á¦ -------- 514
Topic 6. õ½Ä(Asthma) -------- 516
Topic 7. ¾Ë·¹¸£±â ºñ¿°(Allergic rhinitis) -------- 529
PART 5. ¼Òȱâ
Chapter 01. [Drug Class Review] ¼Òȱ⿡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. À§½Äµµ¿ª·ùÁúȯ/¼Òȼº ±Ë¾ç Ä¡·áÁ¦ -------- 552
1-1. ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(Proton pump inhibitor, PPI) -------- 558
1-2. À§»êºÐºñ¾ïÁ¦Á¦: Potassium-Competitive Acid Blockers(PCAB) -------- 572
1-3. À§»êºÐºñ¾ïÁ¦Á¦: Histamine-2 receptor antagonist(H2RA) -------- 577
1-4. Á¦»êÁ¦ -------- 585
1-5. Á¡¸·º¸È£Á¦(Coating agents)/±âŸ ¹æ¾îÀÎÀÚ Áõ°¾àÁ¦ -------- 591
Topic 2. À§Àå°ü¿îµ¿ÃËÁøÁ¦(Prokinetics) -------- 599
Topic 3. Ç×±¸ÅäÁ¦(Anti-emetics) -------- 610
Topic 4. Áö»çÁ¦(Anti-diarrheal agents) -------- 623
Topic 5. º¯ºñ, ¿ÏÇÏÁ¦ -------- 629
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 6. ½Ä¿åºÎÁø/½Ä¿åÃËÁøÁ¦(appetite stimulants) -------- 644
Topic 7. ¸¸¼º º¯ºñ -------- 647
Topic 8. À§½Äµµ¿ª·ùÁúȯ -------- 650
Topic 9. ¼Òȼº ±Ë¾ç/Ç︮ÄÚ¹ÚÅÍ °¨¿° -------- 664
[SUPPLEMENT] ¼Òȼº ±Ë¾ç: NSAIDs ¿¬°ü ±Ë¾ç -------- 668
Topic 10. ±â´É¼º À§ÀåÀå¾Ö -------- 683
10-1. ±â´É¼º ¼ÒȺҷ®Áõ -------- 683
10-2. °ú¹Î´ëÀåÁõÈıº -------- 692
Topic 11. ¿°Áõ¼º ÀåÁúȯ -------- 706
[SPECIAL REVIEW] ±Ë¾ç¼º ´ëÀå¿° vs. Å©·Ðº´ -------- 709
Topic 12. ¸¸¼º BÇü °£¿° -------- 725
Topic 13. ¸¸¼º CÇü °£¿° -------- 734
[SPECIAL REVIEW] Pan-genotypic DAA regimens -------- 745
Vol. 2
PART 6. ³»ºÐºñ
Chapter 01. [Drug Class Review] ³»ºÐºñ¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ºÎ½Å°ÑÁú È£¸£¸ó/±æÇ×Á¦ -------- 4
Topic 2. »ý½Ä»ù È£¸£¸ó/±æÇ×Á¦ -------- 6
2-1. »ý½Ä»ù È£¸£¸ó -------- 6
2-2. »ý½Ä»ù È£¸£¸ó ±æÇ×Á¦ -------- 18
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 3. °©»ó»ù Áúȯ -------- 32
3-1. °©»ó»ù ±â´ÉÀúÇÏÁõ -------- 32
[Âü°í] °©»ó»ù ÁúȯÀ» ÀÌÇØÇϱâ À§ÇÑ ±âÃÊ -------- 32
3-2. °©»ó»ù ±â´ÉÇ×ÁøÁõ -------- 42
Topic 4. ´ç´¢º´ -------- 52
4-1. ´ç´¢º´: Ä¡·á ¹× ¾à¹°¿ä¹ý Overview -------- 52
4-2. ´ç´¢º´: ¾à¹°¿ä¹ý-°æ±¸Ç÷´ç°ÇÏÁ¦ -------- 78
[SUPPLEMENT] Incretin °ü·Ã ¾à¹° -------- 87
4-3. ´ç´¢º´: ¾à¹°¿ä¹ý-ÁÖ»çÁ¦ -------- 96
Topic 5. ÀÌ»óÁöÁúÇ÷Áõ -------- 103
[SPECIAL REVIEW] PCSK9 (Proprotein convertase subtilisin-kexin type 9) ¾ïÁ¦Á¦ -------- 120
Topic 6. ºñ¸¸ -------- 121
[SPECIAL REVIEW] GLP-1 agonist: Liraglutide (Saxenda) -------- 130
Topic 7. °ñ´Ù°øÁõ -------- 142
[SPECIAL REVIEW] °ñ´Ù°øÁõ: ¾à¹°¿ä¹ý: Denosumab (RANKL ´ÜÀÏŬ·ÐÇ×ü) -------- 161
Topic 8. Æó°æ(¿©¼º°»³â±â ÁõÈıº) -------- 178
Topic 9. ³²¼º°»³â±â ÁõÈıº -------- 185
PART 7. ¿ä·Î»ý½Ä±â
Chapter 01. [Drug Class Review] ¿ä·Î»ý½Ä±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö¿¡ »ç¿ëµÇ´Â ¾à¹° -------- 197
Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 2. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö -------- 198
2-1. Àü¸³¼±ºñ´ëÁõ -------- 198
2-2. °ú¹Î¼º ¹æ±¤ -------- 215
[SPECIAL REVIEW] °ú¹Î¼º¹æ±¤: ¾à¹°¿ä¹ý: º£Å¸3 ¾Æµå·¹³¯¸° ¼ö¿ëü ÀÛ¿ëÁ¦: mirabegron -------- 220
2-3. ¿ä½Ç±Ý -------- 226
Topic 3. ³²¼º ¼º±â´ÉÀå¾Ö -------- 234
3-1. ¹ß±âºÎÀü -------- 234
3-2. Á¶·çÁõ -------- 246
PART 8. ½Å°æ/Á¤½Å
Chapter 01. [Drug Class Review] ½Å°æ/Á¤½Å°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. GABA ¹× Glutamate¼º ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 256
[Âü°í] GABA/Glutamate -------- 256
1-1. Benzodiazepine -------- 258
1-2. Barbiturate -------- 269
1-3. Ç׳úÀüÁõÁ¦ -------- 275
[SPECIAL REVIEW] Gabapentenoids: gaba
º»¹®Áß¿¡¼
ÀÌ Ã¥ÀÇ ÁýÇÊ µ¿±â´Â ÇѸ¶µð·Î »ó´ë¸¦ ¾Ë°í ³ª¸¦ ¾Ë¸é ¹é ¹ø ½Î¿öµµ À§Å·ÓÁö ¾Ê´Ù´Â "ÁöÇÇÁö±â ¹éÀüºÒÅÂ" Á¤½ÅÀÔ´Ï´Ù.
ÀÇ»ç ÀÔÀå¿¡¼ "ÁöÇÇ"´Â ´Ù½º·Á¾ß ÇÒ Áúº´ÀÇ Á¤Ã¼¸¦ Á¦´ë·Î ÆÄ¾ÇÇØ¾ß ÇÑ´Ù´Â Àǹ̰ÚÁö¿ä. ¹Ý¸é "Áö±â"´Â ³» ¼Õ¿¡ Áã¾îÁø ¹«±â¸¦ Á¦´ë·Î ¾Ë°í ´É¼÷ÇÏ°Ô »ç¿ëÇØ¾ß ÇÑ´Ù´Â ¶æÀ¸·Î ´Ù°¡¿É´Ï´Ù.
Ȱ¿ë °¡´ÉÇÑ ¹«±â¶õ ¿Ü°ú°è Àǻ翡°Õ ¼ö¼úÀÏ Å×°í, ³»°ú°è Àǻ翡°Ô´Â ´Ü¿¬ÄÚ ¾à¹°À̰ÚÁÒ.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ ¾øÀÌ ¾àÀ» ó¹æÇÏ°í ½ÍÁö ¾Ê¾Ò½À´Ï´Ù. ÇÏÁö¸¸ ¹«¼öÈ÷ ¸¹Àº ¾àÀÌ Á¸ÀçÇϱ⿡ ÀÌµé ¾àÀÇ Á¤Ã¼¸¦ ÇϳªÇϳª ÆÄ¾ÇÇÑ´Ù´Â °Ç ¹«Ã´À̳ª ¹ö°Å¿î °úÁ¤ÀÏ °Ì´Ï´Ù. ¾àÀº ´ë°³ ÀÛ¿ë±âÀüÀ̳ª »ç¿ë ¸ñÀû¿¡ µû¶ó ƯÁ¤ ¾à¹°±º("Drug class")À¸·Î ºÐ·ùµÇ±â ¶§¹®¿¡ "Drug class"º°·Î ¹¾î¼ Ư¡À» ÆÄ¾ÇÇÑ´Ù¸é ¼Ò±âÀÇ ¸ñÀûÀº ´Þ¼ºÇÏ´Â ¼ÀÀ̰ÚÁö¿ä. ÀÌ°Ô ¹Ù·Î º» Ã¥ÀÌ Ãß±¸ÇÏ´Â "Drug class review"ÀÔ´Ï´Ù.
ÇÏÁö¸¸ º» Ã¥Àº ´Ü¼øÈ÷ ¾à¿¡ ´ëÇÑ Á¤º¸¸¸À» Á¦°øÇϱâ À§ÇÑ Ã¥Àº ¾Æ´Õ´Ï´Ù.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ¿¡¼ ÇÑ¹ß ´õ ³ª¾Æ°¡ °¡À̵å¶óÀÎÀ̳ª ±Ù°Å ±â¹ÝÀ¸·Î ¾àÀ» ó¹æÇÏ´Â ½ÇÀüÁöħÀ» Á¦½ÃÇÏ´Â °ÍÀÌ ÀÌ Ã¥ÀÇ ±Ã±ØÀûÀÎ ÁöÇâÁ¡ÀÔ´Ï´Ù. À̰ÍÀÌ ¹Ù·Î "Real world prescription"À̶ó´Â ºÎÁ¦¿¡ ´ã±ä ÀǹÌÀÔ´Ï´Ù.
ÀÇ»ç·Î »ì¾Æ°¡´Â µ¿¾È ¶¼·Á¾ß ¶¿ ¼ö ¾ø´Â °Ô ¾àÀ̱⿡ ¾à¿¡ ´ëÇÑ °í¹ÎÀº Áö¼ÓµÉ ¼ö¹Û¿¡ ¾ø½À´Ï´Ù.
±×·¸Áö¸¸ ²÷ÀÓ¾øÀÌ ½Å¾àÀÌ ½ñ¾ÆÁ® ³ª¿À°í ±âÁ¸ ¾àÀÇ ¿ëµµµµ »õ·Ó°Ô Á¤ÀǵǴ µî ¾à¿¡ ´ëÇÑ ÃÖ½ÅÁ¤º¸¸¦ ¾÷µ¥ÀÌÆ®Çϱâ´Â ½±Áö ¾Ê½À´Ï´Ù.
º» Ã¥ÀÌ ¾à¿¡ ´ëÇÑ À¯¿ëÇÑ Âü°í¼·Î ÀÚ¸®¸Å±èÇÏ¿© ¾àÀ» Á¦´ë·Î ¾Ë°í º¸´Ù ¹Ù¸¥ ó¹æÀ» ³»¸®´Â µ¥ ÀÏÁ¶ÇßÀ¸¸é ÇÏ´Â ¹Ù¶÷ÀÔ´Ï´Ù.
(/ '¼¹®' Áß¿¡¼)
ÀúÀÚ¼Ò°³
»ý³â¿ùÀÏ | - |
---|
ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.
ÁÖ°£·©Å·
´õº¸±â»óǰÁ¤º¸Á¦°ø°í½Ã
À̺¥Æ® ±âȹÀü
Àü°øµµ¼/´ëÇб³Àç ºÐ¾ß¿¡¼ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥
ÆÇ¸ÅÀÚÁ¤º¸
»óÈ£ |
(ÁÖ)±³º¸¹®°í |
---|---|
´ëÇ¥ÀÚ¸í |
¾Èº´Çö |
»ç¾÷ÀÚµî·Ï¹øÈ£ |
102-81-11670 |
¿¬¶ôó |
1544-1900 |
ÀüÀÚ¿ìÆíÁÖ¼Ò |
callcenter@kyobobook.co.kr |
Åë½ÅÆÇ¸Å¾÷½Å°í¹øÈ£ |
01-0653 |
¿µ¾÷¼ÒÀçÁö |
¼¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù) |
±³È¯/ȯºÒ
¹Ýǰ/±³È¯ ¹æ¹ý |
¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹Ýǰ/±³È¯/ȯºÒ¡¯ ¿¡¼ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼ ½Åû °¡´É |
---|---|
¹Ýǰ/±³È¯°¡´É ±â°£ |
º¯½É ¹ÝǰÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É |
¹Ýǰ/±³È¯ ºñ¿ë |
º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹Ýǰ/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã |
¹Ýǰ/±³È¯ ºÒ°¡ »çÀ¯ |
·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óǰ µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óǰ µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·º¹Á¦°¡ °¡´ÉÇÑ »óǰ µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆÇ¸Å°¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì ·ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì |
»óǰ ǰÀý |
°ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ ǰÀý/Áö¿¬µÉ ¼ö ÀÖÀ½ |
¼ÒºñÀÚ ÇÇÇØº¸»ó |
·»óǰÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, ǰÁúº¸Áõ ¹× ÇÇÇØº¸»ó µî¿¡ °üÇÑ »çÇ×Àº¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øÈ¸ °í½Ã)¿¡ ÁØÇÏ¿© ó¸®µÊ ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼ÀǼҺñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ |
(ÁÖ)ÀÎÅÍÆÄũĿ¸Ó½ºÀÇ ¸ðµç »óǰÀº ÆÇ¸ÅÀÚ ¹× °áÁ¦ ¼ö´ÜÀÇ ±¸ºÐ¾øÀÌ È¸¿ø´ÔµéÀÇ ±¸¸Å¾ÈÀüÀ» À§ÇØ ¾ÈÀü°áÁ¦ ½Ã½ºÅÛÀ» µµÀÔÇÏ¿© ¼ºñ½ºÇϰí ÀÖ½À´Ï´Ù.
°áÁ¦´ë±Ý ¿¹Ä¡¾÷ µî·Ï : 02-006-00064
¼ºñ½º °¡ÀÔ»ç½Ç È®ÀÎ
¹è¼Û¾È³»
±³º¸¹®°í »óǰÀº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óǰÀ» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Ãâ°í°¡´É ½Ã°£ÀÌ ¼·Î ´Ù¸¥ »óǰÀ» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óǰÀ» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.
±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.
¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.